• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Suvenphar Share Price

    Suven Pharmaceuticals Share PriceSuven Pharmaceuticals

    Mid Cap 5.6k Result
    ₹655.35
    5.95 (0.92%)
    • Advice
    • Hold
    As on 30 November, 2023 | 07:09 BSE: 543064 NSE: SUVENPHARISIN: INE03QK01018

    Suven Pharmaceuticals Performance

    Day Range

    • Low 643.20
    • High 671.45
    ₹ 655.35

    52 Week Range

    • Low 450.50
    • High 671.45
    ₹ 655.35
    • Open Price652.75
    • Previous Close649.40
    • Volume509064

    Start SIP in Suven Pharmaceuticals

    Start SIP

    Suven Pharmaceuticals Share Price

    • Over 1 Month 15.31%
    • Over 3 Month 29.12%
    • Over 6 Month 37.23%
    • Over 1 Year 42.33%

    Suven Pharmaceuticals Key Statistics

    P/E Ratio 38.6
    PEG Ratio 326.5
    Market Cap Cr 16,683
    Price to Book Ratio 9.6
    EPS 16.6
    Dividend 0
    Relative Strength Index 76.22
    Money Flow Index 91.2
    MACD Signal 10.87
    Average True Range 21.95

    Suven Pharmaceuticals Investment Rating

    • Master Rating:

    • Suven Pharmaceuticals has an operating revenue of Rs. 1,301.73 Cr. on a trailing 12-month basis. An annual revenue de-growth of -2% needs improvement, Pre-tax margin of 42% is great, ROE of 23% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 28% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 8% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 86 which is a GOOD score indicating consistency in earnings, a RS Rating of 67 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 70 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Suven Pharmaceuticals Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 225344364348278339364
    Operating Expenses Qtr Cr 127174190201172184206
    Operating Profit Qtr Cr 97170175147107155158
    Depreciation Qtr Cr 10111111111110
    Interest Qtr Cr 1121012
    Tax Qtr Cr 26434238274055
    Net Profit Qtr Cr 7512413010979114224
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 1,3751,508
    Operating Expenses Annual Cr 747740
    Operating Profit Annual in Cr 583580
    Depreciation Cr 4339
    Interest Annual Cr 56
    Tax Annual Cr 147164
    Net Profit Annual Cr 433558
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 270
    Cash from Investing Activity Annual Cr -90
    Cash from Financing Annual Activity Cr -156
    Net Cash Flow Annual Cr 23
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 1,7491,521
    Fixed Assets Annual Cr 677564
    Total Non Current Assets Annual Cr 1,003696
    Total Current Assets Annual Cr 9551,109
    Total Assets Annual Cr 1,9581,805
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 6960
    ROE Annual % 2537
    ROCE Annual % 3246
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 4758
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 231348369354278339364
    Operating Expenses Qtr Cr 133181200207179188207
    Operating Profit Qtr Cr 98167169147100151157
    Depreciation Qtr Cr 12131212121210
    Interest Qtr Cr 1121012
    Tax Qtr Cr 26434238264170
    Net Profit Qtr Cr 801211241087210892
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 1,3871,413
    Operating Expenses Annual Cr 774741
    Operating Profit Annual in Cr 567579
    Depreciation Cr 4839
    Interest Annual Cr 56
    Tax Annual Cr 148214
    Net Profit Annual Cr 411454
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 330
    Cash from Investing Activity Annual Cr -136
    Cash from Financing Annual Activity Cr -156
    Net Cash Flow Annual Cr 37
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 1,7351,527
    Fixed Assets Annual Cr 828564
    Total Non Current Assets Annual Cr 955702
    Total Current Assets Annual Cr 1,0111,128
    Total Assets Annual Cr 1,9661,830
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 6860
    ROE Annual % 2430
    ROCE Annual % 3139
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 4651
    Invest in Suven Pharmaceuticals

    Suven Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹655.35
    5.95 (0.92%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹598.33
    • 50 Day
    • ₹573.95
    • 100 Day
    • ₹548.27
    • 200 Day
    • ₹522.46
    • 20 Day
    • ₹589.11
    • 50 Day
    • ₹574.00
    • 100 Day
    • ₹537.66
    • 200 Day
    • ₹507.12

    Suven Pharmaceuticals Resistance and Support

    PIVOT
    ₹656.67
    Resistance
    First Resistance 670.13
    Second Resistance 684.92
    Third Resistance 698.38
    RSI 76.22
    MFI 91.20
    MACD Single Line 10.87
    MACD 18.17
    Support
    First Resistance 641.88
    Second Resistance 628.42
    Third Resistance 613.63

    Suven Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 529,340 20,024,932 37.83
    Week 670,798 26,798,380 39.95
    1 Month 348,766 17,326,674 49.68
    6 Month 486,231 31,634,208 65.06

    Suven Pharmaceuticals Result Highlights

    Suven Pharmaceuticals Synopsis

    NSE-Medical-Generic Drugs

    Suven Pharmaceutical is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1330.08 Cr. and Equity Capital is Rs. 25.46 Cr. for the Year ended 31/03/2023. Suven Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 06/11/2018 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24299TG2018PLC128171 and registration number is 128171.
    Market Cap 16,683
    Sales 1,282
    Shares in Float 10.18
    No of funds 154
    Yield 0.18
    Book Value 9.54
    U/D Vol ratio 2.9
    LTDebt / Equity 2
    Alpha 0.15
    Beta 0.07

    Suven Pharmaceuticals

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 60%60%60%60%
    Mutual Funds 12.15%9.12%8.56%8.97%
    Insurance Companies 1.38%0.11%2.26%2.23%
    Foreign Portfolio Investors 10.01%9.5%9.47%8.11%
    Financial Institutions/ Banks
    Individual Investors 11.76%12.8%12.76%14.01%
    Others 4.7%8.47%6.95%6.68%

    Suven Pharmaceuticals Management

    Name Designation
    Mr. Venkateswarlu Jasti Managing Director
    Ms. Deepanwita Chattopadhyay Independent Director
    Dr. Jerry Jeyasingh Non Exe.Non Ind.Director
    Mr. J V Ramudu Chairman, Non Ind & Non Exe Director
    Mr. D G Prasad Independent Director
    Dr. V Sambasiva Rao Independent Director

    Suven Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Suven Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2023-11-09 Quarterly Results
    2023-08-08 Quarterly Results
    2023-05-25 Audited Results
    2023-02-06 Quarterly Results
    2022-11-08 Quarterly Results
    Date Purpose Remarks
    2022-09-12 INTERIM Rs.1.00 per share(100%)Interim Dividend
    2022-09-12 SPECIAL Rs.5.00 per share(500%)Special Dividend
    2022-05-17 INTERIM Re.1.00 per shaer (100%) Second Interim Dividend
    2022-05-17 SPECIAL Rs.1.00 per share(100%)Special Dividend
    2022-02-16 INTERIM Rs.1.00 per share(100%)Interim Dividend

    Suven Pharmaceuticals MF Shareholding

    Name Amount(cr)
    UTI Flexi Cap Fund Regular Plan Growth 24,370
    Axis Small Cap Fund Regular Growth 16,369
    DSP ELSS Tax Saver Fund Regular Plan Growth 11,693
    HSBC Small Cap Fund Fund Regular Growth 11,552
    Quant Small Cap Fund Growth 9,521

    Suven Pharmaceuticals FAQs

    What is Share Price of Suven Pharmaceuticals ?

    Suven Pharmaceuticals share price is ₹655 As on 30 November, 2023 | 06:55

    What is the Market Cap of Suven Pharmaceuticals ?

    The Market Cap of Suven Pharmaceuticals is ₹16682.9 Cr As on 30 November, 2023 | 06:55

    What is the P/E ratio of Suven Pharmaceuticals ?

    The P/E ratio of Suven Pharmaceuticals is 38.6 As on 30 November, 2023 | 06:55

    What is the PB ratio of Suven Pharmaceuticals ?

    The PB ratio of Suven Pharmaceuticals is 9.6 As on 30 November, 2023 | 06:55

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.